Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hunter

Showing results (1221-1230 of 1,249) with videos related to

Pageof 125
Sort By:
European Radiology|July 2, 2022
Multi-center validation of an artificial intelligence system for detection of COVID-19 on chest radiographs in symptomatic patientsMichael D Kuo, Keith W H Chiu, David S Wang, et al.
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.
British Journal of Haematology|April 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemiaShirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, et al.
BMC Medicine|August 30, 2019
The implications of three major new trials for the effect of water, sanitation and hygiene on childhood diarrhea and stunting: a consensus statementOliver Cumming, Benjamin F Arnold, Radu Ban, et al.
Nature Communications|February 10, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's MacroglobulinemiaRomanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
Blood|July 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemiaSteven P Treon, Kirsten Meid, Zachary R Hunter, et al.
Clinical Lymphoma & Myeloma|October 13, 2007
Novel agents in the treatment of Waldenström's macroglobulinemiaSteven P Treon, Evdoxia Hatjiharissi, Xavier Leleu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Venetoclax in Previously Treated Waldenström MacroglobulinemiaJorge J Castillo, John N Allan, Tanya Siddiqi, et al.
Pageof 125

Showing results (1221-1230 of 1,249) with videos related to

Sort By:
Pageof 125
European Radiology|July 2, 2022
Multi-center validation of an artificial intelligence system for detection of COVID-19 on chest radiographs in symptomatic patientsMichael D Kuo, Keith W H Chiu, David S Wang, et al.
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.
British Journal of Haematology|April 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemiaShirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, et al.
BMC Medicine|August 30, 2019
The implications of three major new trials for the effect of water, sanitation and hygiene on childhood diarrhea and stunting: a consensus statementOliver Cumming, Benjamin F Arnold, Radu Ban, et al.
Nature Communications|February 10, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's MacroglobulinemiaRomanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
Blood|July 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemiaSteven P Treon, Kirsten Meid, Zachary R Hunter, et al.
Clinical Lymphoma & Myeloma|October 13, 2007
Novel agents in the treatment of Waldenström's macroglobulinemiaSteven P Treon, Evdoxia Hatjiharissi, Xavier Leleu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Venetoclax in Previously Treated Waldenström MacroglobulinemiaJorge J Castillo, John N Allan, Tanya Siddiqi, et al.
Pageof 125